XD technology is an intensified cell culture process with typical XD titer improvement of 8-10 times and is applicable for multiple biological products such as proteins, fusion proteins and antibodies.
The technology has been employed across a range of mammalian cell systems.
DSM Biologics president Karen King said, "We believe our proprietary XD technology will play an important role in the next generation of biopharmaceutical manufacturing."
Financial details of the transaction were not revealed.
DSM Pharmaceutical Products president and CEO Alexander Wessels said, "DSM continuously strives to provide its clients with added value through our innovative service and technology offerings."